Biogen's Tecfidera MS pill exceeds early expectations
This article was originally published in Scrip
Executive Summary
Demand for Biogen Idec’s multiple sclerosis pill Tecfidera appears to be exceeding expectations, prompting some Wall Street analysts to raise their sales estimates for the newly approved drug.